Immune Thrombocytopenia: A Rare Adverse Event of Vancomycin Therapy.
| Autor: | Obi ES; Department of Health Administration, College of Public Health, East Tennessee State University, Johnson City, USA., Lnu D; Department of Gastroenterology, Dartford and Gravesham NHS Trust, Dartford, GBR.; Medical Education, Liaquat University of Medical and Health Sciences, Jamshoro, PAK., Ehimwenma NO; Department of Internal Medicine, Diana, Princess of Wales Hospital, Grimsby, GBR., Tobalesi O; Department of Internal Medicine, College of Health Sciences, University of Ilorin, Ilorin, NGA., Iklaki W; Department of Internal Medicine, All Saints University School of Medicine, Roseau, DMA., Arslan F; Department of Internal Medicine, Rawalpindi Medical University, Rawalpindi, PAK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 May 22; Vol. 15 (5), pp. e39348. Date of Electronic Publication: 2023 May 22 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.39348 |
| Abstrakt: | Vancomycin, a glycopeptide antibiotic, is widely used for Gram-positive cocci or bacilli bacteria-induced serious infections. Although considered safe and effective, it still causes adverse events. Vancomycin-induced immune thrombocytopenia is a rarely reported adverse event, manifesting from asymptomatic thrombocytopenia to life-threatening bleeding. We underline a case of a 56-year-old male with a diabetic foot with an infected exudating purulent ulcer. He experienced a significant drop in platelet count after commencing vancomycin, and discontinuing vancomycin resulted in improved platelet count with positive vancomycin-induced anti-platelet antibodies. After ruling out other possible causes of thrombocytopenia, a presumptive diagnosis of vancomycin-induced thrombocytopenia was made. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Obi et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|